Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma

Steven G. DuBois(University of California, San Francisco), Araz Marachelian(University of Southern California), Hiroyuki Shimada(National Center for Geriatrics and Gerontology), Rachel A. Kudgus(Mayo Clinic), Julie R. Park(Seattle Children's Hospital), Katherine K. Matthay(University of California System), Najee Boucher(Children's Hospital of Los Angeles), Joel M. Reid(Children's Hospital of Philadelphia), Yaël P. Mossé(Children's Hospital of Philadelphia), Clare J. Twist(Children's Hospital of Los Angeles), Scarlett Czarnecki(Children's Hospital of Los Angeles), Susan L. Cohn(Comer Children's Hospital), Rochelle Bagatell(Children's Hospital of Philadelphia), Brian Weiss(Cincinnati Children's Hospital Medical Center), Elizabeth Fox(Children's National), Meaghan Granger(Cook Children's Medical Center), Jesse Courtier(UCSF Benioff Children's Hospital), Lars M. Wagner(Primary Children's Hospital), Margaret E. Macy(Children's Hospital Colorado), Denice Tsao‐Wei(Children's Hospital of Los Angeles), Susan Groshen(USC Norris Comprehensive Cancer Center), Hollie Lai(Children's Hospital of Orange County), Kelly C. Goldsmith(Emory University), Randall A. Hawkins(UCSF Benioff Children's Hospital), Renee M. McGovern(Mayo Clinic), Chunqiao Luo(Children's Hospital of Los Angeles), Fariba Goodarzian(University of the West of Scotland), Greg Yanik(Michigan Medicine), John M. Maris(Children's Hospital of Philadelphia)
Clinical Cancer Research
August 9, 2018
Cited by 88


Related Papers